zepbound novo nordisk

Order byBest matchMost fresh

Zepbound beats Wegovy for weight loss

Eli Lilly's Zepbound outperforms Novo Nordisk's Wegovy for weight loss in trial

Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as reducing waist circumference, citing data from a head-to-head trial. The data is the first head-to-head trial comparing the wildly popular medicines,

· 2d · on MSN

Lilly’s Zepbound Trims More Belly Fat Than Novo’s Wegovy

· 1d · on MSN

Eli Lilly's Zepbound beat Novo Nordisk’s Wegovy in a big weight loss drug study

What is the most effective weight loss drug?

drug maker Eli Lilly put its own weight loss drug Zepbound against the popular drug Wegovy, and Zepbound outperformed, causing 6% more weight loss than its competitor.

· 1d

New study compares Wegovy and Zepbound for the first time

· 2d

Study finds Zepbound may help people lose more weight than Wegovy

Zepbound trims more belly fat than Wegovy, study shows

The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the rival medicines.

1don MSN

Here’s how much extra weight is lost with Zepbound over Wegovy

At 72 weeks, participants using Zepbound saw an average weight-loss reduction of 20.2% versus 13.7% with Novo Nordisk’s own treatment, Eli Lilly said of the results presented at the European Congress on Obesity and published in the New England Journal of Medicine.

Fierce Biotech39m

Novo Nordisk inks $2.2B deal for Septerna's preclinical obesity programs

Novo Nordisk is making yet another bet on obesity, offering Septerna more than $200 million in upfront and near-term payments for rights to preclinical oral small molecules that hit targets including GLP-1.

Devdiscourse38m

Novo Nordisk and Septerna Team Up for Groundbreaking Obesity Treatments

Novo Nordisk partners with U.S. biotech Septerna in a $2.2 billion deal to develop oral small molecule drugs for obesity and metabolic diseases. This collaboration enhances Novo's position in the expanding obesity market.